Marvel Biosciences Corp. (MRVL.V)
| Previous Close | 0.0900 |
| Open | 0.1000 |
| Bid | 0.0800 x N/A |
| Ask | 0.0950 x N/A |
| Day's Range | 0.0900 - 0.1000 |
| 52 Week Range | 0.0750 - 0.1700 |
| Volume | |
| Avg. Volume | 16,828 |
| Market Cap | 3.581M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1400 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Baystreet
Stocks in play: Marvel Biosciences Corp
And its wholly owned subsidiary, Marvel Biotechnology Inc, announces that it has initiated the 4-week ...
- Newsfile
Marvel Commences Final Study Required Prior to Initiating Human Trials
Calgary, Alberta--(Newsfile Corp. - March 21, 2023) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that it has initiated the 4-week good laboratory practice (GLP) FDA investigational new drug (IND) enabling dose-ranging dog studies for its lead drug candidate MB-204."This dog study is the last of the two key primary animal studies we need to complete before entering phase ...
- Newsfile
Marvel Biosciences Initiates Four Week Rat GLP Toxicology Study
Calgary, Alberta--(Newsfile Corp. - March 9, 2023) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that it has initiated the 4-week good laboratory practice (GLP) FDA investigational new drug (IND) enabling dose-ranging rat studies for its lead drug candidate MB-204."This rat study, along with the GLP study on dogs, are the last two key studies we need to complete ...
